A network meta-analysis of the effectiveness of biological agents, including rituximab, abatacept, belimumab, anifrolumab, obinutuzumab, ocrelizumab, and low-dose IL-2, in 1,480 patients with lupus nephritis revealed that a significant proportion of patients achieving complete remission had received low-dose IL-2, obinutuzumab, rituximab, and belimumab (114). Here, IL2 is linked to lupus nephritis.